German researchers have revealed a possible reason for the failure of nervous aromatic tumor treatment, and they indicated a new strategy to combat tumors in particular.
Aromi nervous tumor is a cancer that mainly affects children, develops from the cells of the friendly nervous system, and often affects children under the age of five.
The study was conducted by a team led by Yan Dor and Anton Hinsen of the Experimental and Sarlective Research Center in Germany, and published in the “Cancer Discovery” magazine on August 7, and was written by the Yurik Alert website.
Some tumors sometimes decrease without treatment and some grow very quickly, and these tumors often respond well to chemotherapy at the beginning, but they usually return after a year to two years.
The aggressive nervous tumor cells are characterized by an abnormally high number of copies of the MYCN.
The team has discovered that the “JinMy CN” site plays an important role in the aggression of nervous aromatic tumor: if it is present in a specific place, the cancer cells enter into a state of lethargy, and thus become immune to treatment.
The research team proposes a new therapeutic strategy targeting inactive tumor cells, and their approach has already been successful in the laboratory mouse model.
Sleeping cells survive the treatment
“It was especially difficult to treat.”
He explains: “We wanted to know exactly what the gene does in cancer cells, how it can affect the expression of other genes, and how tumors can be destroyed more effectively in the future.”
Hensen has shown, about the instability of the genomic in children’s tumors, previously that these tumor genes are often not found on chromosomes in cell nuclei, but rather on many small DNA molecules with a throat shape within cancer cells.
“When these cells are divided, this DNA is randomly distributed to nascent cells, unlike the chromosome DNA,” he says, as a result, as a result, neurons can contain a mixture of cells, some of which contain large numbers of MYCN genes, others contain very few numbers.
Through experiments conducted on cultivated cells, mice models, and samples of patients, the researchers managed to demonstrate that aggressive cells with many copies of the “JinMWCN” are alone that destroy chemotherapy.
He explains the role of: “On the other hand, the tumor cells with a few versions of MYCN remain alive, and they enter into a kind of deep sleep.”
It can wake up from this deep sleep with completely incomprehensible waking gifts, which contributes to the return of cancer.
“There are drugs that specifically target hacker, or sleeper cells,” says Dor.
He and his team showed that the combination of chemotherapy – which eliminates fast -growing cells with numerous MIC’s versions – and a second drug that targets hacker cells can significantly improve the results of treatment of neuroma tumor.